Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I'm going to have to peel off a few myself for taxes. After that 24 to 36 months, I'm looking for over 100.
I know it's optimistic but it sure happen, especially if he does something smart with the cash.
Please forgive me, I'm getting a little bit excited. It's kind of going to be that way since I've been waiting since the 1990s for this action to happen with how many numerous disappointments like a few of the guys around here. I feel like I'm somewhere in super position.
With HALO & HGEN, both up over a dollar . CDMO is sure to follow. I'm watching HGEN closely as it should be a major catalyst for us....
Better believe it is, but we just have to wait them out. The forces of all this positive news can't be held long.
Profitable, margins going up, 100% growth, and it just goes on and on.
To top it off if the market tanks we're still in good shape. Oh we may go down some but not much, and not for long.
They'll try never to let it close above 20. If they do, then the funds with the bylaws on $20 stocks minimum will be coming in. My prediction is that they try to hold it on the 20 at the close because I believe plenty of blind will come in if we're above 20.
Waiting to see if they play that game today where they bring it all the way back down to 19 at the end of the day.
No doubt about it it's collusion. According to SEC regulations strictly illegal. But you could never prove it.
Believe me if one fun comes in we're up two or three bucks, and if two or three institutions decide to come in we're up five bucks.
Now they might play that b******* game give no bid and then scoop up on some stop losses but that's not going to be enough shares.
Tight isn't even the word for it. The only way they're able to gather shares is to come off the bid and drop the price a dollar. After doing a couple days of that and not getting very much they're just going to have to buy up. These are most likely institutions just adding shares, and if a new player wants to come in and pick up 2-. 300,000 shares you got two or three dollars on the PPS.
Make mistake about it, will be well over 20 by the time the CC runs around..
That is my firm belief.
Today......Covid 19 and variants
Worldwide, deaths are on the rise again, running at around 12,000 per day on average, and new cases are climbing too, eclipsing 700,000 a day.
"This is not the situation we want to be in 16 months into a pandemic, where we have proven control measures," said Maria Van Kerkhove, one of the World Health Organization's leaders on Covid-19.
In Brazil, where deaths are running at about 3,000 per day, accounting for one-quarter of the lives lost worldwide in recent weeks, the crisis has been likened to a "raging inferno" by one WHO official. A more contagious variant of the virus has been rampaging across the country.
As cases surge, hospitals are running out of critical sedatives. As a result, there have been reports of some doctors diluting what supplies remain and even tying patients to their beds while breathing tubes are pushed down their throats.
The slow vaccine rollout has crushed Brazilians' pride in their own history of carrying out huge immunization campaigns that were the envy of the developing world.
Lenzilumab is the first and only anti-human GM-CSF treatment to be tested in the NIH ACTIV-5/BET-B clinical trial. Lenzilumab is being investigated in combination with remdesivir and will be compared with remdesivir alone. Two hundred hospitalized patients 18 years old and greater who need medical care for COVID-19 infection will be enrolled and randomized, half of whom will receive lenzilumab. The evaluation of lenzilumab in this Phase 2 trial began in October 2020 and is expected to be completed in the second half of 2021. Humanigen is also exploring the effectiveness of its GM-CSF neutralization technologies (either through the use of lenzilumab as a neutralizing antibody or through GM-CSF gene knockout) in combination with other CAR-T, bispecific or natural killer (NK) T-cell-engaging immunotherapy treatments to break the efficacy/toxicity linkage, including to prevent and/or treat Graft versus Host Disease (GvHD) in patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT).
Sell off in the market is supposed to be due to coronavirus concerns. The worst the concerns the higher we should go. I suppose the question is how long will it take investors to figure it out. No more than a few days.....
On the CC she said margins will continue to improve up to the 40%, industry standard. This should greatly improve the bottom line since SG&A shouldn't move much from current levels.
I'd like to see a q with 10 to 20 cents profit.
Any guesses on what that horde of cash will be doing?
I wonder if someone lives in the area could drop in on them and see what's going on?
I have little doubt that they will get approved. But if I remember correctly the CC you said they were contributing around 35 million already. .
Two things I'm most concerned about is how quickly we can ramp up and what are we going to do with all that cash.
What seems to be a nice positive is how well he manages expectations and profits. If past CC's are any indication will beat on revenue and profits albeit small numbers now.
Market Overview
The Global Pharmaceutical CDMO Market was valued USD 160.12 billion in 2020, and it is expected to reach USD 236.61 billion by 2026, registering a CAGR of 6.5%, during the period of forecast period (2021-2026). The CMO/CDMO service sector is uniquely positioned to address some of the challenges that drug developers are facing amid the COVID-19 pandemic. This pandemic has impacted multiple aspects of the pharma and biopharma industry, from drug development, clinical trials, supplies, manufacturing, to supply chain logistics. However, the drug shortages due to COVID-19 are limited, and they are expected to remain so for short-term, due to stockpiles of pharmaceuticals, APIs, globally.
As a result of the growing demand for generic medicines and biologics, the capital-intensive nature of the business, and the complex manufacturing requirements, many pharmaceutical companies have identified the potential profitability in contracting with a CMO (contract manufacturing outsourcing) for both clinical and commercial stage manufacturing.
The biggest factor driving the growth of CMOs in the pharmaceutical industry is the growing need for state-of-the-art processes and production technologies, which have proven highly effective in meeting regulatory requirements.
The United States is one of the largest R&D spenders in the pharmaceutical and biotechnology sector. According to Axios, a prominent online news company in the United States, as of 2018, pharmaceutical industries in the country had the tenth-highest average after-tax profit levels, when compared to more than 100 different industries. While drug companies are responsible for 23% of the US health revenue, they also make 63% of the total profits.
R&D sections of several pharmaceutical companies, especially operating at small scales, were condensed after the emergence of CRO players. As more CROs have started to offer research services with valuable cost, they won the competition with in-house pharmaceutical R&D departments. CROs also follow several strategies to stay ahead of top pharmaceutical players.
Availability of Real-world data for drug development
Another important issue for 2021 will be the ability of pharmaceutical companies to make use of real-world data for which patient data is collected outside of randomized controlled trials. This approach is important for drug development because it evaluates if outcome-based reimbursement models for drugs can be successful?
Personalized Medicine and Value-Based Healthcare
Personalized medicine has the potential to revolutionize the healthcare and CDMO industry. The introduction of diagnostic and informatics approaches has enabled scientists to understand the molecular basis of disease, particularly genome. The detailed account of an individual’s genetic make-up can help research-oriented healthcare companies to include or exclude a specific individual on a timely basis.
Ultimately, it will lead to faster and smaller medical trials leading to lower costs of research. In fact, pharmaceutical companies are in better shape to develop medicines for individual patients that are based on the genome of the patient.
There is no doubt that the concept of personalized and precision medicine is a new research endeavor that can offer products tailored to individual patients. It provides an opportunity for companies to increase the quality of care rather than focusing on quantity.
These advances and trends will be contributing to the growth of the global CDMO industry. Keeping in view the mentioned trends, 2021 can prove to be an important year for the healthcare industry.
That's definitely the smart way to play it. I figure about two more years is when the big money starts hitting....
Could be sooner let's see what they do with the cash.
Upgraded to QB. OTC...
Mosaic ImmunoEngineering Inc.
Common Stock
4.00
0.20
5.26%
3.25 / 4.00 (100 x 321)
Mosaic ImmunoEngineering Inc. Announces Upgrade to OTCQB
Mosaic ImmunoEngineering Inc. Announces Upgrade to OTCQB Venture Market and Upcoming Presentation at the B. Riley Oncology Investor Conference
Tuesday, January 19, 2021 8:00 AM
Share this article now
? ? ?
Topic:
Company Update
NOVATO, CA / ACCESSWIRE / January 19, 2021 / Mosaic ImmunoEngineering Inc., (the "Company" or "Mosaic") (OTC PINK:CPMV), a development-stage biotechnology company focused on bridging immunology and engineering to develop novel immunotherapies to treat and prevent cancer and infectious diseases, announced today that it will begin trading on the OTCQB® Venture Market as of today, January 19, 2021. The Company also announced today that Steven King, Mosaic's president and chief executive officer, will present a company overview at the B. Riley Securities Oncology Investor Conference on Wednesday, January 20, 2021, at 2:00 p.m. ET. Two hours following the presentation, a replay will be available on the Mosaic Investors/Events webpage for 30 days. The Company's corporate website is located at www.mosaicie.com.
"Our new listing status on the OTCQB® Venture Market is another step toward building stockholder value as we continue to advance our technology platforms. This upgrade creates a greater ease for broker dealers and their customers to trade our stock which is important toward increasing our stock's liquidity and the visibility of the Company to a broader range of investors," stated Steven King, president and chief executive officer of Mosaic. "We look forward to further increasing investor awareness through our participation in the upcoming B. Riley Oncology Investor Conference as well as through additional presentations and publications in the weeks ahead."
About Mosaic ImmunoEngineering Inc.
Mosaic ImmunoEngineering Inc. is a development-stage biotechnology company focused on bridging immunology and engineering to develop novel immunotherapies to treat and prevent cancer and infectious diseases. Mosaic's core technology platform is based on Cowpea Mosaic Virus ("CPMV") which is non-infectious to humans or other animals but upon intra-tumoral administration, elicits a strong innate immune response resulting in potent anti-tumor activity against the primary and distant tumor sites. The broad potential of our lead candidate, MI-O-101, for the treatment of many different types of cancer and potential combination therapies continues to be supported by numerous publications and grant funding through our university collaborators. In addition, the core technology has a potential application as part of a modular vaccine platform which has already generated promising data in both cancer and infectious disease preclinical models, including COVID-19. The vaccine research is currently being performed by one of our co-founders and is funded by the National Science Foundation with viral neutralization testing being performed by the National Institute of Allergy and Infectious Diseases (NIAID). For additional information about Mosaic, please visit MosaicIE.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. For example, we are using forward-looking statements when we discuss Mosaic's future operations and its ability to successfully advance the product candidates; the nature, strategy and focus of Mosaic's business; and the development and commercial potential and potential benefits of any of Mosaic's product candidates. Mosaic may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Because such statements deal with future events and are based on Mosaic's current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of these forward-looking statements could differ materially from those described in or implied by the statements in this press release, including: the uncertainties associated with raising capital to support our development programs , which may not be available on favorable terms or at all; advancing Mosaic's product candidates into clinical trials, the clinical development and regulatory approval of Mosaic's product candidates, including potential delays in the commencement, enrollment and completion of clinical trials; the potential that earlier preclinical studies of Mosaic's product candidates may not be predictive of future results; risks related to business interruptions, including but not limited to, the outbreak of COVID-19 coronavirus, which could seriously harm Mosaic's financial condition and increase its costs and expenses. The foregoing review of important factors that could cause actual events to differ from expectations should not be construed as exhaustive and should be read in conjunction with statements that are included herein and elsewhere, including the risks discussed in Mosaic's filings with the Securities and Exchange Commission. Except as otherwise required by law, Mosaic disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date hereof, whether, as a result of new information, future events or circumstances or otherwise.
Contact:
Jay Carlson, Investor Relations
Mosaic ImmunoEngineering Inc.
info@mosaicie.com
Still holding a couple thousand shares... .
We definitely need to see what's going on.
We seem to be in the best space regardless of general market conditions. Avid bioscience is well positioned with growth good contract backlog and many positives going forward.
I don't see a much better opportunity anywhere else given the safety of a recession proof business.
Someone sent me a private message and I lost it. If you could please resend it I'd appreciate it.
Me too. Looks like A made it to IHUB board. Looks like March 4th next year.
It's really holding well.
Going about has expected. It's amazing that we can get financing for about the market cap of avid just a year ago and not really lose a step at 20 bucks a share. I just want to know what they're going to do with all that cash.
Can someone tell me what's going on now?
I can add the whole story since you can read about me in past PRS
Can someone bring me up the speed here what's going on.. I work with garb and John Rossi many years ago. They did a hell of a job in Germany putting together those E-Waste plants.
You're right, you never know what's going to happen. I can name a dozen of them that I made big money in.
PTSC EDIG ASTV ...
EDIG was a monster. .002 to 22 dollars....
At one time I was the third largest shareholder of garb. You don't know how much I really appreciate everybody buying this stock.
I have well over 100 million.
Remember this. I bought it 32 cents so much too early.
Stock Surge Rescues Tiny Techniclone From Brink
BY EDMUND SANDERS
MARCH 11, 2000 12 AM PT
Four months ago, the prognosis for tiny Techniclone Corp. was bleak. The developer of experimental cancer treatments had run out of cash and laid off half the staff. The stock price languished at 27 cents a share. Even the company’s clinical trials--its only hope for survival--were about to fold for lack of funds.
What a difference Wall Street can make.
Thanks largely to investors’ latest obsession with the biotechnology sector, Techniclone shares have zoomed nearly 4,000% in three months, magically wiping away the company’s cash crunch.
ADVERTISEMENT
The stock surge is an increasingly common story in today’s fast-moving market, but Techniclone’s abrupt reversal of fortune--from the verge of bankruptcy to a Wall Street high-flier--is a dramatic example of just how influential such market mood-swings can be for a struggling company.
At Christmas, Techniclone was worth less than $25 million. Today its market value is nearly $1 billion.
“We’re amazed,” said John Bonfiglio, a onetime organic chemist who now is Techniclone’s interim president.
I never go for that scam never put a stop loss in.
Check your insulin levels, there might be something going on here, so just be on the safe side.
This is the most ridiculous trading I've ever seen. Everybody wants shares at the same price. There are no shares at this price so the market maker takes it down tripping all the stop losses and stealing those shares.